Proposal for cervical cancer screening in the era of HPV vaccination

키워드

참고문헌 (78)

1. Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)[DOI]
2. "GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0" (2013)[URL]
3. Vaccarella S, "50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence", Br J Cancer, 111, pp.965~969 (2014)[DOI]
4. Vaccarella S, "Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study", Lancet Oncol, 17, pp.1445~1452 (2016)[DOI]
5. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014", Cancer Research and Treatment, 49(2), pp.292~305 (2017), 대한암학회
6. de Sanjose S, "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study", Lancet Oncol, 11, pp.1048~1056 (2010)[DOI]
7. Sycuro LK, "Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students", J Infect Dis, 198, pp.971~978 (2008)[DOI]
8. Koshiol J, "Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis", Am J Epidemiol, 168, pp.123~137 (2008)[DOI]
9. Forman D, "Global burden of human papillomavirus and related diseases", Vaccine, 30(Suppl 5), pp.F12~F23 (2012)[DOI]
10. Bouscarat F, "External genital warts (condylomata)", Ann Dermatol Venereol, 143, pp.741~745 (2016)[DOI]
11. Ronco G, "Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial", Lancet Oncol, 11, pp.249~257 (2010)[DOI]
12. Leinonen M, "Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting", J Natl Cancer Inst, 101, pp.1612~1623 (2009)[DOI]
13. Almonte M, "Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines", Best Pract Res Clin Obstet Gynaecol, 25, pp.617~629 (2011)[DOI]
14. Santin AD, "Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial", J Virol, 82, pp.1968~1979 (2008)[DOI]
15. Meszner Z, "Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine", Int J Pediatr Otorhinolaryngol, 79, pp.262~266 (2015)[DOI]
16. Yu Z, "Recurrent laryngeal papillomatosis: the current treatment and future development", Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 29, pp.2107~2110 (2015)
17. Luxembourg A, "Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine", Hum Vaccin Immunother, 11, pp.1313~1322 (2015)[DOI]
18. Garcon N, "Development of an AS04- adjuvanted HPV vaccine with the adjuvant system approach", BioDrugs, 25, pp.217~226 (2011)[DOI]
19. Yokomine M, "Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females", Exp Ther Med, 13, pp.1500~1505 (2017)[DOI]
20. Markowitz LE, "Prevalence of HPV after introduction of the vaccination program in the United States", Pediatrics, 137, pp.e20151968~ (2016)[DOI]
21. Naud PS, "Sustained efficacy, immunogenicity, and safety of the HPV-16", 18 AS04-adjuvanted vaccine: final analysis of a long-term followup study up to 9.4 years post-vaccination, 2014, pp.10, 2147~2162
22. Hildesheim A, "Efficacy of the HPV-16", 18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16, Vaccine, pp.2014, 32[DOI]
23. Paavonen J, "Efficacy of human papillomavirus (HPV)-16", 18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women, 2009, pp.374, 301~314
24. FUTURE II Study Group, "Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions", N Engl J Med, 356, pp.1915~1927 (2007)[DOI]
25. Joura EA, "A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women", N Engl J Med, 372, pp.711~723 (2015)[DOI]
26. Villa LL, "Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18", Vaccine, 24, pp.5571~5583 (2006)[DOI]
27. Hariri S, "Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States", Cancer, 121, pp.2775~2781 (2015)[DOI]
28. Petrosky EY, "Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003-2010", Int J Infect Dis, 33, pp.137~141 (2015)[DOI]
29. Mesher D, "HPV serology testing confirms high HPV immunisation coverage in England", PLoS One, 11, pp.e0150107~ (2016)[DOI]
30. Carter JJ, "Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection", J Infect Dis, 181, pp.1911~1919 (2000)[DOI]
31. Harper DM, "Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial", Lancet, 367, pp.1247~1255 (2006)[DOI]
32. Olsson SE, "Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6", 11, 18 L1 virus-like particle (VLP) vaccine, pp.Vaccine, 2007[DOI]
33. Fischer S, "Shift in prevalence of HPV types in cervical cytology specimens in the era of HPV vaccination", Oncol Lett, 12, pp.601~610 (2016)[DOI]
34. Kavanagh K, "Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16", 18 and closely related HPV types, 2014, pp.110, 2804~2811
35. Bhatia R, "Use of HPV testing for cervical screening in vaccinated women--Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study", Int J Cancer, 138, pp.2922~2931 (2016)[DOI]
36. Bae, Jeong-Hoon, "Human Papillomavirus (HPV) Type Distribution in Korean Women: A Meta-Analysis", Journal of Microbiology and Biotechnology, 18(4), pp.788~794 (2008), 한국미생물·생명공학회
37. Lee HS, "Human papillomavirus genotyping using HPV DNA chip analysis in Korean women", Int J Gynecol Cancer, 17, pp.497~501 (2007)[DOI]
38. 김민정, "Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women", Obstetrics & Gynecology Science, 56(02), pp.110~120 (2013), 대한산부인과학회[DOI]
39. 소경아, "Human Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea", 대한암예방학회지, 21(2), pp.104~109 (2016), 대한암예방학회[DOI]
40. Oh JK, "Type-specific human papillomavirus distribution in invasive cervical cancer in Korea, 1958-2004", Asian Pac J Cancer Prev, 11, pp.993~1000 (2010)
41. Jun JK, "Effectiveness of an organized cervical cancer screening program in Korea: results from a cohort study", Int J Cancer, 124, pp.188~193 (2009)[DOI]
42. Dickinson J, "Recommendations on screening for cervical cancer", CMAJ, 185, pp.35~45 (2013)[DOI]
43. Moyer VA, "Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement", Ann Intern Med, 156, pp.880~891 (2012)[DOI]
44. Saslow D, "American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer", Am J Clin Pathol, 137, pp.516~542 (2012)[DOI]
45. 이재관, "Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition", Journal of Gynecologic Oncology, 24(2), pp.186~203 (2013), 대한부인종양학회
46. 민경진, "The Korean guideline for cervical cancer screening", Journal of Gynecologic Oncology, 26(3), pp.232~239 (2015), 대한부인종양학회
47. Korea Centers for Disease Control and Prevention, "Cheif of KCDC, conference of public health and ministry of education was held in Gokseong where had the highest HPV vaccination rate (press release in 25th April, 2017)", Korea Centers for Disease Control and Prevention, ~ (2017)
48. Korea Centers for Disease Control and Prevention, "National immunization program "Up to 3 times difference" regional disparity in HPV NIP vaccination rate (press release in June 2017)", Korea Centers for Disease Control and Prevention, ~ (2017)
49. "National immunization program" (2017)[URL]
50. Wheeler CM, "Cross-protective efficacy of HPV-16", 18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, 2012, pp.13, 100~110
51. Tabrizi SN, "Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study", Lancet Infect Dis, 14, pp.958~966 (2014)[DOI]
52. Woestenberg PJ, "No evidence for cross-protection of the HPV-16", 18 vaccine against HPV-6, J Infect, pp.2017, 74[DOI]
53. Westra TA, "Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands", BMC Infect Dis, 13, pp.75~ (2013)[DOI]
54. Howell-Jones R, "Declining genital Warts in young women in england associated with HPV 16", 18 vaccination: an ecological study, 2013, pp.208, 1397~1403
55. Tota JE, "Evaluation of type replacement following HPV16", 18 vaccination: pooled analysis of two randomized trials, 2017, pp.109, djw300~
56. Chao C, "Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system", Am J Obstet Gynecol, 216, pp.151~ (2017)
57. Hirth JM, "Effect of number of human papillomavirus vaccine doses on guideline adherent cervical cytology screening among 19-26 year old females", Prev Med, 88, pp.134~139 (2016)[DOI]
58. Wright TC Jr, "Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with highrisk HPV+ cytology-negative results", Am J Clin Pathol, 136, pp.578~586 (2011)[DOI]
59. Khan MJ, "The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of typespecific HPV testing in clinical practice", J Natl Cancer Inst, 97, pp.1072~1079 (2005)[DOI]
60. Castle PE, "Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study", BMJ, 339, pp.b2569~ (2009)[DOI]
61. Jeronimo J, "Secondary prevention of cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline summary", J Oncol Pract, 13, pp.129~133 (2017)[DOI]
62. Giorgi Rossi P, "Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference", Prev Med, 98, pp.21~30 (2017)[DOI]
63. Kim JJ, "Optimal cervical cancer screening in women vaccinated against human papillomavirus", J Natl Cancer Inst, 109, pp.djw216~ (2017)[DOI]
64. Meijer CJ, "Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older", Int J Cancer, 124, pp.516~520 (2009)[DOI]
65. Franco EL, "Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination", Vaccine, 24(Suppl 3), pp.S3 (2006), 171~S3[DOI]
66. Cuzick J, "Overview of the European and North American studies on HPV testing in primary cervical cancer screening", Int J Cancer, 119, pp.1095~1101 (2006)[DOI]
67. Kusanagi Y, "Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype", Am J Pathol, 177, pp.2169~2175 (2010)[DOI]
68. Palmer TJ, "HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study", Br J Cancer, 114, pp.582~589 (2016)[DOI]
69. Valdez M, "Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china", Int J Cancer, 138, pp.1453~1461 (2016)[DOI]
70. Zhao FH, "An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China", Cancer Prev Res (Phila), 6, pp.938~948 (2013)[DOI]
71. Carozzi F, "Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial", Lancet Oncol, 14, pp.168~176 (2013)[DOI]
72. Carozzi F, "Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial", Lancet Oncol, 9, pp.937~945 (2008)[DOI]
73. Uijterwaal MH, "Triaging HPV-positive women with normal cytology by p16", Ki-67 dual-stained cytology testing: baseline and longitudinal data, 2015, pp.136, 2361~2368
74. Wright TC Jr, "Triaging HPV-positive women with p16", Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial, 2017, pp.144, 51~56
75. Wentzensen N, "Performance of p16", Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population, 2012, pp.18, 4154~4162
76. Kreimer AR, "Efficacy of fewer than three doses of an HPV-16", 18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials, 2015, pp.16, 775~786
77. Winer RL, "A Cluster-randomized trial to evaluate a mother-daughter dyadic educational intervention for increasing HPV vaccination coverage in American Indian girls", J Community Health, 41, pp.274~281 (2016)[DOI]
78. Krantz L, "Increasing HPV vaccination coverage through providerbased interventions", Clin Pediatr (Phila), 57, pp.319~326 (2018)[DOI]

관련 논문AI추천